GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
NEW YORK, March 22, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of DaVita Inc. (“DaVita”) (NYSE:DVA) between August 5, 2015 and October 21, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of Colorado. To get more information go to:
http://www.zlk.com/pslra/davita-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) DaVita and its senior executives purposefully steered patients into needless insurance plans to maximize profits; (2) DaVita was using American Kidney Fund to facilitate these inappropriate practices; (3) therefore DaVita’s revenues and profits were illegally acquired; (4) as a result, DaVita lacked effective internal controls over financial reporting.
On January 6, 2017, the Wall Street Journal published an article revealing that DaVita had received subpoenas from federal prosecutors seeking “the production of information related to charitable premium assistance” in connection with DaVita’s ties to the American Kidney Fund, a charity that helps patients pay for kidney dialysis.
If you suffered a loss in DaVita you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
